全球ANNAR生物标志物研究:局部晚期/转移性尿路上皮癌与非肌层浸润性膀胱癌的FGFR变异检测分析
该研究基于全球ANNAR生物标志物研究,使用QIAGEN therascreen FGFR实时PCR试剂盒检测2706例mUC和962例NMIBC archival肿瘤组织,评估有效FGFR检测结果比例、检测失败原因及FGFRalt比例。mUC有效检测率86%,NMIBC为66%(p<0.001);样本存档时间越长、转移灶样本有效检测率越低。FGFRalt在mUC中占19%,NMIBC中占53%。
要点
- mUC有效FGFR检测率86%,显著高于NMIBC的66%(p<0.001)。
- 原发肿瘤样本有效检测率92%,高于转移灶的55%(p<0.001)。
- FGFRalt在mUC中占19%,NMIBC中占53%。
核心结论
- 确保有效FGFR检测结果需关注充足肿瘤样本量、RNA质量、较短存档时间和原发肿瘤样本。
研究设计与样本
- 全球ANNAR生物标志物研究分析,使用QIAGEN therascreen FGFR实时PCR试剂盒检测2706例mUC和962例NMIBC的存档肿瘤组织。
主要发现
- mUC和NMIBC有效检测结果比例分别为86%和66%,差异显著(p<0.001)。
- mUC存档样本<1年有效检测率89%,≥3年77%(p<0.001);NMIBC<1年72%,≥3年43%(p<0.001)。
- mUC原发肿瘤有效检测率92%,转移样本55%(p<0.001);上尿路与下尿路疾病相似(87% vs 86%,p=0.7)。
- 检测失败常见原因为肿瘤含量低和RNA不足。
- FGFRalt在mUC中占19%(83%突变,15%融合),NMIBC中占53%(92%突变,6.3%融合)。
临床怎么用
- 对mUC和NMIBC患者进行FGFR检测时,优先选择原发肿瘤样本、缩短样本存档时间并确保足够肿瘤含量和RNA质量。
局限性
- 缺乏样本采集方法数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Successful fibroblast growth factor receptor alterations (FGFRalt) testing is essential for identifying patients eligible for erdafitinib. This analysis of the global ANNAR biomarker study assessed the proportion of valid fibroblast growth factor receptor (FGFR) test results, reasons for test failure, and proportion of FGFRalt in locally advanced/metastatic urothelial cancer (mUC) and non-muscle-invasive bladder cancer (NMIBC). METHODS: Archival tumor tissue was tested using the QIAGEN therascreen FGFR real-time polymerase chain reaction kit, an approved companion diagnostic for erdafitinib. KEY FINDINGS AND LIMITATIONS: A total of 2706 mUC and 962 NMIBC samples were tested. The proportion of valid test results was significantly different between mUC and NMIBC (86% and 66%, respectively; p < 0.001), which declined with older archival sample age for both mUC (<1 yr 89% and ≥3 yr 77%; p < 0.001) and NMIBC (<1 yr 72% and ≥3 yr 43%; p < 0.001). For mUC, the proportion of valid test results was higher for the primary tumor than for metastatic samples (92% and 55%, respectively; p < 0.001) but similar between upper and lower tract disease (87% and 86%, respectively; p = 0.7). Common reasons for test failure were low tumor content and insufficient RNA. FGFRalt were found in 19% of mUC (83% mutations; 15% fusions) and 53% of NMIBC (92% mutations; 6.3% fusions) samples. Limitations include the lack of data on sample collection method. CONCLUSIONS AND CLINICAL IMPLICATIONS: This is the first and largest report on factors affecting FGFR test results. To ensure valid FGFR test results, adequate tumor sample amount, RNA quality, short archival sample age, and primary tumor samples are important factors.
引用
- Matsubara N, Loriot Y, Banek S, et al. Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study. Eur Urol Oncol. 2025. PMID: 40987680. doi:10.1016/j.euo.2025.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。